GlassScriptPhysician profile
Amanda Speicher
NPI 1376843011
$7,517.94
in general payments reported to CMS, 2019-2025
17 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $512 · 2021: $936 · 2022: $825 · 2023: $1,310 · 2024: $1,087 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,111 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,111.46 |
| Education | $186.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,280.92 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $958.88 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $816.96 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $745.77 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Allergan, INC. | $713.26 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $654.70 | 2020-2025 | Caplyta |
| Lundbeck LLC | $573.64 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $448.39 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $322.37 | 2019-2022 | |
| Alkermes, INC. | $298.45 | 2019-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $247.83 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $174.62 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $173.78 | 2019-2024 | Invega Sustenna, Spravato, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $43.87 | 2025 | Cobenfy |
| Eisai INC. | $27.12 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.92 | 2024 | |
| Avanir Pharmaceuticals, INC. | $15.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Speicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.